Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030654 · ClinicalTrials.gov registry record · Phase 3
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
NCT00030654 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 21 participants.
The verdict
NCT00030654, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as luteinizing hormone-releasing hormone agonist, flutamide, and bicalutamide may stop the adrenal glands from producing androgens. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy given at the same time as hormone therapy is more effective than chemotherapy given after hormone therapy in treating prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy given at the same time as hormone therapy with that of chemotherapy given after hormone therapy in treating patients who have prostate cancer.
Interventions
- DRUG docetaxel
- DRUG doxorubicin hydrochloride
- DRUG bicalutamide
- DRUG flutamide
- DRUG estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2002-10 |
| Est. Completion | 2005-02-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030654
The ClinicalTrials.gov registry entry for NCT00030654 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which docetaxel is the first listed.
NCT00030654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030654 about?
NCT00030654 is a clinical study titled "Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer". RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as luteinizing hormone-releasing hormone agonist, flutamide, and bicalutamide may stop the adrenal glands from producing androgens. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing s...
What is the current status of trial NCT00030654?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2002-10. Estimated completion is 2005-02-04.
What interventions are being tested in trial NCT00030654?
The interventions under investigation include: docetaxel (DRUG), doxorubicin hydrochloride (DRUG), bicalutamide (DRUG), flutamide (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00030654?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.